Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Host Genetics and Clinical Setting in Machine Learning Models: Predicting COVID-19 Prognosis for Healthcare Decision-Making (The FeMiNa Study).

Diagnostics (Basel, Switzerland)·2026
Same author

Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories.

British journal of clinical pharmacology·2025
Same author

A novel colorimetric assay for early differentiation of mucocutaneous and cutaneous leishmaniasis via species-specific identification.

Talanta·2025
Same author

Click chemistry-based dual nanosystem for microRNA-122 detection with single-base specificity from tumour cells.

Journal of nanobiotechnology·2024
Same author

MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer.

Molecular oncology·2024
Same author

Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Sep 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

Amplification-Free Testing of microRNA Biomarkers in Cancer.

Bahareh Soleimanpour1,2,3,4,5, Juan Jose Diaz Mochon2,3,4,5, Salvatore Pernagallo1

  • 1Destina Genomica S.L., Parque Tecnológico de la Salud de Granada (PTS), Avenida de la Innovación 1, Edificio BIC, 18016 Granada, Spain.

Cancers
|August 28, 2025
PubMed
Summary

Developing amplification-free technologies is crucial for reliable cancer diagnostics. These PCR-free methods overcome limitations of traditional PCR, enabling accurate detection of circulating microRNAs for precision medicine.

Keywords:
PCR-free technologiesamplification-free platformsbiomarker analysiscancer diagnosticsearly detectionlabeling-free detectionliquid biopsymicroRNAs (miRNAs)multiplexed assaysnucleic acid testingsensor-based detection

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
09:48

Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein

Published on: July 27, 2016

12.0K

Related Experiment Videos

Last Updated: Sep 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
09:48

Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein

Published on: July 27, 2016

12.0K

Area of Science:

  • Biomolecular detection
  • Molecular diagnostics
  • Cancer research

Background:

  • Circulating microRNAs (miRNAs) show promise as cancer biomarkers.
  • Current polymerase chain reaction (PCR)-based methods face limitations like complex workflows, error proneness, and difficulty detecting low-abundance miRNAs, hindering clinical translation.

Purpose of the Study:

  • To review and highlight the importance of developing amplification-free (PCR-free) technologies for microRNA diagnostics.
  • To emphasize the need for improved reliability, scalability, and practicality of miRNA detection in clinical settings.

Main Methods:

  • Review of recent advancements in PCR-free technologies over the past five years.
  • Focus on innovative methods like bead-based assays and sensor detection platforms as alternatives to PCR.

Main Results:

  • PCR-free technologies offer streamlined workflows, reduced error rates, and broad clinical sample compatibility.
  • These methods enable absolute quantification without nucleic acid extraction, reverse transcription, or amplification.
  • Simultaneous detection of multiple miRNAs in a single assay is achievable, providing cost-effective biomarker profiling.

Conclusions:

  • The transition to PCR-free technologies represents a significant advancement in microRNA diagnostics.
  • These methods overcome technical barriers, facilitating broader adoption in routine clinical practice.
  • This shift supports precision medicine and enhances early cancer detection capabilities.